TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male and female patients aged 18-70 years (both included).~2. Clinical diagnosis of persistent asthma (according to GINA guidelines 2009 update) for at least 6 months prior to screening.~3. Screening FEV1 value of 60% \< FEV1 ≤ 85% of the predicted normal value.~4. FEV1 reversibility ≥ 12% and an absolute increase of at least 200 ml over baseline value after inhalation of 400µg (four inhalations) of salbutamol.~5. Pre-dose FEV1 value of first treatment period within the range of ± 20% of the FEV1 measured at screening prior to salbutamol inhalation.~6. Patients on a stable dose and regimen~Exclusion Criteria:~1. Current smokers, former smokers within the last 6 months, or ex-smokers with a history of more than 10 pack-years.~2. Patients diagnosed with COPD.~3. Recent Respiratory tract infections within 6 weeks before Screening Visit.~4. Intubation (ever) or hospitalization for longer than 24 hours for the management of an asthma exacerbation within the preceding 6 weeks of the screening visit.~5. Clinically significant respiratory conditions.~6. Clinically significant cardiovascular conditions.~7. Patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry.~8. Clinically relevant abnormalities laboratory, ECG parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation.~9. Patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- LAS100977 0.625 μg (Type: EXPERIMENTAL): Single-dose LAS100977 0.625 μg, during double-blind treatment period
- LAS100977 1.25 μg (Type: EXPERIMENTAL): Single-dose LAS100977 1.25 μg, during double-blind treatment period
- LAS100977 2.5 μg (Type: EXPERIMENTAL): Single-dose LAS100977 2.5 μg, during double-blind treatment period
- Salbutamol (Type: ACTIVE_COMPARATOR): Single-dose salbutamol 400 μg, during double-blind treatment period
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to LAS100977, and placebo to salbutamol
- LAS100977 0.313 μg (Type: EXPERIMENTAL): Single-dose LAS100977 0.313 μg, during double-blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Men and women age 18 and older~* 6-36 months after kidney transplant receiving cyclosporine or tacrolimus~* calculated GFR ≥35 and ≤75mL/min/1.73 m²~* subjects must have completed 1 year in the IM103-010ST and remained on study treatment (Long Term Extension)~Key Exclusion Criteria:~* Significant infection~* acute rejection within 3 months~* prior graft loss due to rejection~* pregnancy~* positive crossmatch

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Belatacept (Type: EXPERIMENTAL): None
- B: calcineurin inhibitor (CNI)-based immunosuppressive regimen (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Generally good health~* History of recurrent herpes labialis with at last three episodes during the prior 12 months~Exclusion Criteria:~* Treatment with antivirals or immunosuppressive agents within 2 weeks prior to randomization~* Pregnant and/or nursing women~* Continuous daily treatment with pain medication~* Significant skin condition that occur in the area of herpes recurrences

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ME-609
- 2 (Type: ACTIVE_COMPARATOR): Acyclovir in ME-609 vehicle
- 3 (Type: PLACEBO_COMPARATOR): Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Children may be eligible for this study if they:~* Are 3 to 12 years old (consent of parent or guardian required).~* Are HIV-positive.~* Are receiving combination anti-HIV therapy. He/she must have been taking this combination for at least 16 weeks, and it must include either 2 NRTIs alone or 2 NRTIs plus either an NNRTI or a PI. (This study has been changed. This no longer has to be a child's first anti-HIV drug combination.)~* Have a viral load greater than 10,000 copies/ml while taking this anti-HIV drug combination.~* Have never received treatment with a PI or an NNRTI. (One or two doses are allowed.)~* Have never taken at least 1 NRTI.~Exclusion Criteria~Children will not be eligible for this study if they:~* Are receiving treatment for an opportunistic (AIDS-related) or serious bacterial infection at the time of study entry.~* Are receiving chemotherapy for cancer.~* Have certain serious diseases (other than HIV) or conditions.~* Have received or are currently receiving certain medications.~* Are pregnant.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Nuedexta on Bulbar Physiology and Function in ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable-definite ALS (El-Escorial Criterion);~* ALSFRS-R Bulbar subscale score \<10~* Bamboo oral reading speaking rate \<140 words per minute~* No allergies to barium sulfate.~Exclusion Criteria:~* Treatment for sialorrhea within the past 3 months that includes either Botox or radiation treatment~* Participation in another disease modifying study targeting bulbar or cough function~* Use of invasive mechanical ventilation/presence of tracheostomy~* Advanced frontotemporal dementia or significant cognitive dysfunction~* Nil per oral status for feeding (i.e., NPO, nothing by mouth)~* Previously prescribed Nuedexta. Additionally, if participants are taking Riluzole or other medications to control sialorrhea, they must be on a stable dose for at least 30 days prior to enrollment in the current study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- ALS individuals with bulbar dysfunction (Type: EXPERIMENTAL): Participants enrolled in this group will be prescribed dextromethorphan HBr and quinidine sulfate (Nuedexta) as recommended by their treating neurologist. 20 mg dextromethorphan HBr and 10mg quinidine sulfate will be administered orally with 1 capsule every day for the initial 7 days followed by 1 capsule every 12 hours for the remaining 23 days of the study. Participants will be evaluated 30 days apart to determine the impact of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women who are 20 - 75 years old~* HbA1c of ≥7.0% and \<10.5%~* FPG of ≤ 270 mg/dL~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before run-in period~Exclusion Criteria:~* Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes~* Patients with serious diabetic complications~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification~* Patients with severe hepatic disorder or severe renal disorder.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin + Teneligliptin (Type: EXPERIMENTAL): Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
- Placebo + Teneligliptin (Type: PLACEBO_COMPARATOR): Patients receive placebo for 24 weeks in combination with Teneligliptin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult ≥18 years of age~2. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other authorized or approved assay in any specimen collected within 72 hours prior to enrollment.~   Note - An exception must be requested to the Sponsor if ≥72 hours since positive test.~3. Hospitalized in participating facility.~4. Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g., chest x-ray or CT scan).~5. Abnormal respiratory status that is judged worse than baseline by the investigator and as documented at any point within 24 hours prior to randomization, consistent with ordinal scale levels 5, 6 or 7, specifically defined as:~   * Room air saturation of oxygen (SaO2) \< 93%, OR~  * Requiring supplemental oxygen, OR~  * Tachypnea with respiratory rate ≥30~6. Patient or proxy is willing and able to provide written informed consent and comply with all protocol requirements~Exclusion Criteria:~1. Contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator.~2. Clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than COVID-19~3. Receipt of other investigational therapy as a part of another clinical trial. Note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVID-19 Convalescent plasma (Type: EXPERIMENTAL): COVID-19 Convalescent plasma on Study Day 1 in addition to standard care
- Standard care (Type: NO_INTERVENTION): Standard care alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or nonpregnant, nonlactating female subjects~* Meets criteria for definite rheumatoid arthritis as defined by 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification at screening~* Has active disease defined as a score of \>3.2 on DAS28-ESR prior to study drug administration despite dual-DMARD treatment~* Is on a stable dose of ≤ 20 mg per week of methotrexate for at least 8 weeks AND a stable dose of an allowed DMARD for at least 24 weeks prior to the screening visit~* May also be on a stable dose of 10 mg or less of prednisone or other the dose equivalent of another corticosteroid for 4 weeks prior to study drug administration~Exclusion Criteria:~* Has current rheumatoid disease or inflammatory joint disease other than RA~* Has any history of use of adrenocorticotropic hormone (ACTH) for the treatment of RA~* Has taken B-cell mediated therapies in the 6 months prior to screening~* Has hepatitis B, hepatitis C, history of tuberculosis (TB) or other contraindication as per the United States (US) Prescribing Information for Acthar~* Has history of Type 1 or Type 2 diabetes~* Has any clinically significant infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: All Enrolled Participants (Type: EXPERIMENTAL): All participants receive Acthar Gel 1 mL twice weekly for 12 weeks
- Part 2: Acthar Gel (Type: EXPERIMENTAL): Participants receive Acthar Gel 1 mL twice weekly for an additional 12 weeks
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Participants receive Placebo 1 mL twice weekly for an additional 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV)~* currently treated with either oral haloperidol, quetiapine fumarate, or olanzapine for 4 months prior to trial entry~* Positive and Negative Syndrome Scale (PANSS) total score of \<=80 and score \<= 4 on each of the following PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content~* body mass index \<= 35 at start of study.~Exclusion Criteria:~* Meet DSM-IV criteria for Axis I diagnosis other than schizophrenia or diagnosis of substance dependence (except nicotine or caffeine dependence)~* history of neuroleptic malignant syndrome, a rare psychotropic-drug reaction, which may be characterized by confusion, reduced consciousness, high fever or pronounced muscle stiffness~* history of disease of the central nervous system, such as stroke, Parkinson's disease, Alzheimer's disease, or Huntington's disease~* known hypersensitivity, intolerance, or unresponsiveness to risperidone~* pregnant or nursing females, or those lacking adequate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have Type 2 Diabetes (T2DM) with HbA1c ≥7% to ≤10% at screening, on stable therapy for the last 3 months prior to screening. T2DM may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or glucagon like peptide-1 receptor agonists (GLP-1 RAs)~* Have a BMI of ≥27 kg/m²~* Are overweight or have obesity~* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight~* Are at least 18 years of age and age of majority per local laws and regulations~Exclusion Criteria:~* Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except T2DM~* Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \>270 mg/dL(on 2 nonconsecutive days) prior to Visit 3~* Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment~* Have self-reported change in body weight \>5kg within 3 months prior to screening~* Have had a history of chronic or acute pancreatitis~* Change in body weight greater than 5 kg within 3 months prior to starting study~* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity~* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)~* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years~* Any lifetime history of a suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 milligrams (mg) Tirzepatide (Type: EXPERIMENTAL): 10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW)
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg Tirzepatide administered SC QW
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC QW

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet the diagnostic criteria for immune thrombocytopenia.~2. Untreated hospitalized patients, may be male or female, between the ages of 18 \~ 80 years.~3. To show a platelet count \< 30×10\^9/L, and with bleeding manifestations.~4. Eastern Cooperative Oncology Group（ECOG）performance status ≤ 2.~5. Willing and able to sign written informed consent~Exclusion Criteria:~1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit.~2. Received high-dose steroids or \[2\] intravenous immunoglobulin transfusion(IVIG)in the 3 weeks prior to the start of the study.~3. Current HIV infection or hepatitis B virus or hepatitis C virus infections. Severe medical condition (lung, hepatic or renal disorder) other than ITP. 4.Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)~5.Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period.~6.Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.~7.Patients who are deemed unsuitable for the study by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- combination treatment group (Type: EXPERIMENTAL): 120 enrolled patients are randomly picked up to take Rituximab in combination with Rh-TPO at the indicated dose.
- single treatment group (Type: ACTIVE_COMPARATOR): 120 enrolled patients are randomly picked up to take Rituximab at the indicated dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* • Patients who are immunocompetent and who have had 4 or more episodes of Recurrent Genital Herpes (RGH) in the last 12 months.~  * Patients with active HSV-2 or HSV-1 infection as confirmed by Polymerase Chain Reaction (PCR).~ * Patients with active symptoms (i.e., itching, burning, tingling, aching, tenderness, rash or pain) associated with a recurrent episode of genital herpes~Exclusion Criteria:~* • Female patients who are pregnant or breast-feeding.~  * Current, history or suspicion of liver disease or kidney disease.~ * HIV infected (as confirmed by positive HIV serology).~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doripenem in the Treatment of Ventilator-Associated Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has received mechanical ventilation for \> 24 hours~* Presence of a new or progressive infiltrate on chest x-ray~Exclusion Criteria:~* Believed at study entry to have ventilator-associated pneumonia caused solely by pathogen(s) resistant to certain antibiotics~* History of moderate or severe hypersensitivity reactions to certain antibiotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete